Document Type

Journal Article

Department/Unit

School of Chinese Medicine

Language

English

Abstract

Interference of the binding of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) has become a new inspiring immunotherapy for resisting cancers. To date, the FDA has approved two PD-1 monoclonal antibody drugs against cancer as well as a monoclonal antibody for PD-L1. More PD-1 and PD-L1 monoclonal antibody drugs are on their way in clinical trials. In this review, we focused on the mechanism of the PD-1/PD-L1 signaling pathway and the monoclonal antibodies (mAbs) against PD-1 and PD-L1, which were approved by the FDA or are still in clinical trials. And also presented is the prospect of the PD-1/PD-L1 immune checkpoint blockade in the next generation of immunotherapy.

Keywords

Immunotherapy, PD-1 (Programmed cell death protein 1), PD-L1 (Programmed death-ligand 1), monoclonal antibodies (mAbs)

Publication Date

7-2016

Source Publication Title

International Journal of Molecular Sciences

Volume

17

Issue

7

Start Page

1151

Publisher

MDPI

Peer Reviewed

1

Copyright

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

DOI

10.3390/ijms17071151

Link to Publisher's Edition

http://dx.doi.org/10.3390/ijms17071151

ISSN (print)

16616596

ISSN (electronic)

14220067

Share

COinS